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Summary
The production of Interleukin 6 (IL6) was studied during experimental cerebral malaria (ECM)
induced by Plasmodium berghei ANKA (PbA) infection . IL6 is present in the serum of mice with
ECM, the highest concentrations being observed in mice with full-blown neurological syndrome.
High IL6 levels were also observed, however, in the absence of pathology in nonlethal malaria
infection. These data suggest that IL6 is produced in large amounts during malaria infection,
but does not play a major role in the pathogenesis ofECM . A modulation of IL6 production
in ECM was achieved by in vivo treatment with other anticytokine antibodies: antibodies to
interferon (IFN-'y) or to tumor necrosis factor (TNF) abolished the rise of 11,6, while anti-IL3
and anti-granulocyte/macrophage colony-stimulating factor antibodies only partially prevented
this rise, suggesting that the two cytokines IFN--y and TNF are important intermediates in IL6
production . Passive immunization against IL6 did not prevent ECM, but significantly reduced
serum IgG levels in malaria-infected mice. Thus, by its effects on B cells, IL6 may be involved
in hypergammaglobulinemia and immune-complex diseases, e.g., glomerulonephritis observed
during malaria infection .
Experimental cerebral malaria (ECM) is a hyperacute le-
thal syndrome reproducing some features ofhuman ce-
rebral malaria (1), the most severe complication and cause
ofdeath ofPlasmodiumfalciparum infection (2) . We have shown
that (a) ECM is strictly dependent upon the presence ofT
cells (3) and is accompanied by a marked expansion of mono-
cyte/macrophage pool in lymphoid organs (4) ; (b) overproduc-
tion of TNF plays a`central pathogenic role (5) ; and (c) a
cascade ofT cell-derived cytokines is required for this TNF
overproduction to occur (4, 6) .
IL6 is a cytokine with pleiotropic effects that can be pro-
duced by a variety of cell types (7, 8), including monocytes,
T cells, and endothelial cells (9), which are central to the
lesion ofCM (5) . Also, it has been shown that the synthesis
and release of 11,6 can be induced by TNF (10, 11) . There-
fore, we have analyzed the possible contribution of IL6 to
the pathogenesis of ECM .
Materials and Methods
Mice .
￿
Female CBA/Ca mice, originally obtained from Bom-
holtgard (Ry, Denmark) and bred in our laboratory, were 6-8 wk
old at the time of infection .
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Infection.
￿
P . bergheiANKA (PbA) infection was initiated as de-
scribed (3) . 17XNL Plasmodium yoeliiwas from Dr. J.H.L. Playfair
(Middlesex Hospital, London, UK) .
11,6 Assay .
￿
11,6 activity was assayed by using the 7TD1 bio-
assay (7) revealed by MTT (12) . The 7TD1 hybridoma cell line
waskindlydonatedby Dr. J . Van Snick, LudwigInstitute, Brussels,
Belgium .
Anticytokine Antibodies.
￿
Rabbit anti-mouse TNF (5), anti-
mouse 11,3, and anti-mouse granulocyte/macrophage (GM)-CSF
(4) antisera (produced in our laboratory), and rat anti-mouse IFN-y
(F3) IgG2amAb (13) were injected in malaria-infected animals fol-
lowing protocols previously shown to be protective against ECM
(4-6) . 6114, a rat IgG1 anti-murine IL6 mAb (500NU/ml on 1 U
of murine rIL6, one neutralizing unit (NU) being defined as the
reciprocal ofthe dilution of the antibody leading to a 50% inhibi-
tion of I1,6-induced growth of 7TD1 cells), was kindly donated
by Dr. J . Van Snick (14) and used as ascitic fluid .
Immunoglobulin Assays.
￿
Serum IgG and IgM levels were mea-
sured using ELISA, according to a procedure derived from that
o£ Izui et al . (15) .
Antimalarial Antibodies.
￿
Serum anti-P . berghei antibodies were
measured by ELISA and by slide immunofluorescence as previously
described (3) .
Statistical Analysis.
￿
Means were compared using the nonpara-
metric MannWhitney test .
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Kinetics ofIL6 during Malaria Infection .
￿
Series of mice that
are genetically susceptible toCM(CBA/Ca) were inoculated
with PbAinfected erythrocytes, and bled daily from day 4
to day 7 . Serum IIr6 remained in the range of noninfected
mice (<15 U/ml) before the 7th day of malaria infection .
As can be seen in Fig. 1, elevated serum IL6 levels were al-
ready seen in mice with early signs of neurological syndrome
(i.e., isolated palsies, mild ataxia, referred to as "early CM")
(n = 4) . The highest IL-6 serum levels were observed in mice
with full-blown cerebral malaria, which occurs in 80-90%
of PbA-infected mice (5) (hemi- or tetraplegia, convulsions,
severe ataxia, tendency to roll over upon stimulation, and even-
tually coma, referred to as "CM") (n = 9) . Serum IL6 levels
were also markedly elevated on day 7 of the nonlethal Plas-
modium yoelii infection (n = 10), and gradually returned to
normal by day 21, thus following a pattern very similar to
the parasitemia in these animals (Fig . 2) .
Modulation of11,6 by Anticytokine Antibodies .
￿
As can be
seen on Fig. 3, the rise in serum I1r6 concentrations was com-
pletely abolished in mice treated with antiTNF (seven mice
tested, p< 0.001) or anti-IFN-y antibodies (eight mice tested,
p < 0.001), whereas the combined treatment with anti-IL-3
and anti-GM-CSF antibodies, which totally prevents the rise
ofTNF (4), only partially (although significantlyp = 0.02)
reduced the 11,6 production in infected mice (nine mice tested) .
Effects ofAnti-IL6 Antibody Treatment.
￿
20 CBA/Ca mice
were infected with PbA and 10 were injected intraperitoneally
on days 0 and 4 with 0.2 ml of 6114mAb ormedium as con-
trol . In anti-II,6 mAb-treated infected mice, IL-6 was not
detected in the serum at day 7 or 8 of infection (<15 U/ml,
9 mice tested) . However, anti-IIT6mAb failed to preventECM,
which developed in 8 of 10 mice, as in 8 of 10 infected un-
treated mice. Anti-II,6 mAb treatment significantly reduced
the malaria-associated rise in serum IgG as detected on day
7 ofinfection (Table 1), but had no effect onIgM levels . Treat-
ment of PbA-infected mice with another ratmAb (anti-IFN-
-y) did not affect serum IgG levels (Table 1) . In contrast to
total IgG, serum-specific antimalarial antibody levels were
not affected by anti-IL6 mAb treatment (221.4 ± 46.2OD
units by ELISA and 2,478.6 ± 1,505 .8 titration units by im-
munofluorescence) compared to 165.3 ± 45.7 OD units and
2,041 ± 1,745.5 in control infected mice.
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Figure 1 .
￿
Serum IL6 levels on
day 7 after infection by PbA in
CBA/Ca mice. (NMS) Normal
mouse serum: age- and sex-
matched CBA/Ca mice ; early
CM: starting neurological syn-
drome ; fullCM: full-blown neu-
rological syndrome. See text for
explanations. Results are expressed
as means ± SEM .
Discussion
Interleukin 6 Production in Experimental Cerebral Malaria
Figure 2 . Kinetics of serum
11,6 during nonlethal malaria .
CBA/Ca mice (n = 10) were in-
fected with P . yoelii. Results are
expressed as means ± SEM .
In this paper we show that IL -6 is produced in consider-
able amounts during blood stage infection by malaria para-
sites, and that this cytokine may be involved in hypergam-
maglobulinemia rather than in the pathogenesis of the cerebral
complications . Our results also indicate that malaria-induced
11,6 production depends upon other cytokines, since it can
be modulated by anticytokine antibodies administered in vivo.
At least one signal for IL-6 production is provided by TNF,
as shown on brain macrophages or astrocytes in vitro (16),
since antiTNF antibody treatment prevents the rise of IL6
in serum of plasmodium-infected mice, in agreement with
experiments in Escherichia coli LPS-injected baboons (16) . The
rise in malarial-induced serum IL6 was abolished by anti-
IFN-y antibody but only partially prevented by the dual treat-
ment with anti-IL3 and anti-GM-CSF antibodies. In other
models, both IIr1 (9) and IFN-,y (11) also have a role in IIr6
production . Several infectious diseases have been already
reported to induce IL6 (17-20) . In the context of malaria,
11,6 has been found in mice after sporozoite infection (21)
and in man with severe falciparum infection (22) . IL6, at
least in vitro, can be produced by brain cells (16, 23), in addi-
tion to the three cell types involved in ECM.
While 11,6 is induced by TNF (10, 11), two arguments
do not support major role of11,6 in the pathogenesis ofECM .
Figure 3 .
￿
Modulation of serum IL6 levels by in vivo treatment with
anticytokine antibodies. While antiTNF and anti-IFN--y antibodies to-
tally prevent the rise of serum IL-6, the combined treatment by anti-11,3
and anti-GM-CSF antibodies only partially reduces IL6 levels . The rela-
tion with the protection is shown on the bottom line . See Materials and
Methods for doses and schedule of injection of the antibodies. Results
are expressed as means ± SEM .Table 1.
￿
Effect of Anti-IL-6 mAb on Serum IgG and IgM Levels in PbA-Infected Mice.
Time after
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IL6 has been found to lead to maturation of activated B
cells into Ig-secreting plasma cells (26) . Since anti-IL6 mAb
We thank Dr. J . Van Snick for providing 7TD1 and 6B4 cells, and Dr. B. Allet and John Delarnarter
(Glaxo IMB, Carouge, Switzerland) for providing recombinant murine TNF, 11,3, and GM-CSF. The
technical assistance ofD . Gretener, C. Gysler, and C. Schwerdel is gratefully acknowledged .
This work is supported by grant 870107 (to G.E . Grau) from the United Nations Development Pro-
gram/World Bank/World Health Organization Special Programmefor Research and Training in Tropical
Diseases, grants 3.803.086 (to P.-H . Lambert), 3.650.0.87 (to P . Vassalli), and 3.930.0.87 (A . Fontana)
from the Swiss National Science Foundation and theSandoz Research Foundation . G.E . Grau is supported
by the Cloetta Foundation, Zurich, Switzerland .
Address correspondence toDr. Georges E. Grau, World Health Organization-Immunology Research and
Training Centre, Department of Pathology, University ofGeneva, 1 rue Michel-Servet, CH-1211 Gencve
4, Switzerland .
Received for publication 7 March 1990 and in revisedform 30 July 1990.
1. Grau,G.E ., P.F. Piguet, P . Vassalli, and P.H. Lambert. 1989 .
Tumor necrosis factor and other cytokines in cerebral malaria :
experimental and clinical data . Immunol . Rev . 112:49 .
2 . Taylor, T.E .,M.E. Molyneux,J.J. Wirima, K.A . Fletcher, and
1507
￿
Grau et al .
￿
Brief Definitive Report
prevents hypergammaglobulinemia without reducing the
specific antimalarial humoral response, one has to hypothe-
size that cytokines other than 1176 (such as IL-2 and IL,4)
are more instrumental in specific antibody responses . IL6 is
thus possibly involved in malarial complications associated
with hypergammaglobulinemia . In addition, overexpression
of 11,6 hasbeen suggested in the development ofB cell lym-
phomas (27) . IL6production might contribute to the higher
frequency of Burkitt's lymphomas associated with plasmo-
dium infections in epidemiological studies (28) . The
significance of IL-6 production in malaria may thus go be-
yond the cerebral syndrome.
K. Morris . 1988 . Blood glucose levels in Malawian children
before and during the administration of intravenous quinine
for severe falciparum malaria. N . Engl .J . Med . 319:1040 .
3. Grau,G.E ., P.F. Piguet, H.D. Engers,J.A . Louis, P . Vassalli,
PbA Treatment IgG
,cg/ml
p IgM
,ugltnl
P
.
Day 0 7,975 ± 1,520 180 ± 40
Day 4 control 15,420 ± 3,490 - 202 ± 50 -
anti-IL-6 10,780 ± 800.. NS 275 ± 19 NS
Day 7 control 21,333 ± 3,280 - 532 ± 75 -
anti-IL-6 mAb 10,280 ± 2,700 0.017 481 ± 86 NS
anti-IFN-.y mAb 25,562 ± 4,405 NS ND NDand P.H . Lambert . 1986 . L3T4' T lymphocytes play a major
role in the pathogenesis of murine cerebral malaria .J. Immunol.
137:2348.
4 . Grau,G.E .,V Kindler, P.F. Piguet, P.H . Lambert, andP . Vas-
salli . 1988 . Prevention of experimental cerebral malariaby an-
ticytokine antibodies . IL3 and GM-CSF are intermediates in
increased TNF production and macrophage accumulation .J.
Exp . Med . 168:1499.
5 . Grau, G.E ., L.F. Fajardo, P.F. Piguet, B. Allet, P.H . Lambert,
and P . Vassalli . 1987. Tumor necrosis factor (cachectin) as an
essential mediator in murine cerebral malaria . Science (Wash.
DC. 237:1210.
6 . Grau,G.E ., H. Heremans, P.F. Piguet, P . Pointaire, P.H. Lam-
bert, A. Billiau, and P . Vassalli . 1989 . Monoclonal antibody
against interferon-gamma can prevent experimental cerebral
malaria and its associated overproduction of tumor necrosis
factor. Proc. Natl. Acad. Sci. USA . 86:5572 .
7 . Van Snick, J., S . Cayphas, A. Vink,C. Uyttenhove,PG. Coulie,
M. Rubira, andR.J . Simpson . 1986 . Purification and NHz-
terminal amino acid sequence of a Tcell derived lymphokine
with growth factor activity for B-cell hybridomas. Proc Natl.
Acad. Sci . USA . 83:9679.
8 . Kishimoto, T 1989 . Thebiology of interleukin 6. Blood. 74 :1 .
9 . Sironi, M., F . Breviario, P . Proserpio, A. Biondi, A. Vecchi,
J . van Damme,E. Dejana, andA. Mantovani. 1989 . IL1 stimu-
lates IL6 production in endothelial cells .J. Immunol . 142:549 .
10 . Vandamme, J., G. Opdenakker, R.J . Simpson,M.R . Rubira,
S . Cayphas, A. Vink, A. Billiau, and J. Van Snick . 1987 .
Identification of the human 26-kD protein, interferon (3, as
a B cell hybridoma/plasmacytoma growth factor induced by
interleukin 1 andtumor necrosis factor .J. Exp Med. 165:914 .
11 . Brouckaert, P., D.R . Spriggs, G. Demetri, D.W. Kufe, and
W . Fiers . 1989 . Circulating interleukin-6 During aContinuous
Infusion of Tumor Necrosis Factor and Interferon-Gamma.J.
Exp . Med . 169:2257 .
12 . Mosmann, T 1983 . Rapid colorimetric assay for cellular growth
and survival : application to proliferation andrytotoxicity assays.
J. Immunol . Methods. 65 :55 .
13 . Heremans,H .,R. Dijkmans,H. Sobis, F . Vandekerckhove, and
A. Billiau . 1987 . Regulation by interferons of the local inflam-
matory response to bacterial lipopolysaccharide . J. Immunol .
138:4175 .
14 . Vink,A., P . Coulie, P . Wauters, R.P. Nordan,andJ.Van Snick.
1988 . B cell growth and differentiation activity ofinterleukin-
HPl and related murine plasmacytoma growth factors. Syn-
ergy with interleukin 1 . Eur . J. Immunol . 18:607 .
15 . Izui, S.,R.A . Eisenberg, andF.J . Dixon . 1979 . IgMrheuma-
toid factors in mice injected with bacterial lipopolysaccharides .
J. Immunol . 122:2096 .
16 . Fong, YM ., K.J . Tracey, L.L . Moldawer, D.G. Hesse, K.B .
Manogue, J.S . Kenney,AT Lee, G.C . Kuo, A.C . Allison, S.F .
Lowry, andA. Cerami . 1989 . Antibodies to cachectin tumor
necrosis factor reduce interleukin-l-beta and interleukin-6 ap-
1508 Interleukin 6 Production in Experimental Cerebral Malaria
pearance during lethal bacteremia.J. Exp. Med . 170:1627 .
17 . Frei,K., UV Mailpiero, T.P. Leist, R.M . Zinkernagel,M.E .
Schwab, andA. Fontana. 1989 . On the cellular source and func-
tion of interleukin-6 produced in the central nervous system
in viral diseases . Eur . J . Immunol . 19:689 .
18 . Waage, A., P . Brandtzaeg, A. Halstensen, P. Kierulf, andT
Espevik . 1989 . Thecomplex pattern ofcytokines in serum from
patients with meningococcal septic shock . Association between
interleukin 6, interleukin 1 and fatal outcome . J. Exit Med .
169:333 .
19 . Housslau, F.A ., K. Bukasa,C.J.M. Sindic,J . Vandamme, and
J . VanSnick . 1988 . Elevated levels ofthe 26 khumanhybridoma
growth factor (interleukin 6) in cerebrospinal fluid of patients
with acute infection of the central nervous system . Clin . Exp .
Immunol . 71:320 .
20 . Frei, K., T.P . Leist, A. Meager, P . Gallo, D . Leppert, R.M .
Zinkernagel, and A. Fontana . 1988 . Production of B cell
stimulatory factor-2 and interferon gamma in the central
nervous system during viral meningitis and encephalitis . Evalu-
ation in amurine model infectionand in patients.J. Exp. Med .
168 :449 .
21 . Mazier,D ., J . Goma, S. Pied,L. Renia, A. Nussler, F. Miltgen,
R. Legrand, D. Mattei, G.E . Grau, andM . Gentilini . 1990 .
Hepatic phase of malaria : a crucial role as "go-between" with
other stages . Bull. WHO In press.
22 . Kern, P., C.J . Hemmer, J . Vandamme, H.J . Gruss, andM.
Dietrich . 1989 . Elevated tumor necrosis factor-alpha and
interleukin-6 serum levels as markers for complicated plas-
modium-falciparum malaria . Am . J. Med . 87:139 .
23 . Vankelecom,H., P . Carmeliet, J . VanDamme,A. Billiau, and
C. Denef . 1989 . Production ofinterleukin-6by folliculo-stellate
cells of the anterior pituitary gland in a histiotypic cell aggre-
gate culture system . Neuroendocrinol. 49:102 .
24 . Talmadge, J.E ., O . Bowersox, H . Tribble, S.H . Lee, H.M .
Shepard, andD. Liggit . 1987 . Toxicity oftumor necrosis factor
is synergistic with gamma-interferon andcanbe reduced with
cyclooxygenase inhibitors. Am .J. Pathol. 128:410.
25 . Piguet, P.F ., G.E . Grau, and P . Vassalli . 1990. Subcutaneous
perfusion of tumor necrosis factor induces local proliferation
of fibroblasts, capillaries, andepidermal cells, or massive tissue
necrosis. Am . J. Pathol. 136:103 .
26 . Muraguchi, A ., T Hirano, B. Tang, T Matsuda, Y Horii,
K. Nakajima, and T Kishimoto . 1988 . The essential role of
B cell stimulatory factor 2 (BSF-2/IL6) for the terminal differen-
tiation of B cells.J. Exp. Med . 167:332 .
27 . Kawano, M., T . Hirano, T . Matsuda, T . Taga, Y . Horii, K.
Iwato,H. Asaoku, B . Tang,O. Tanabe,H. Tanaka,A . Kura-
moto, andT Kishimoto . 1988 . Autocrine generation and re-
quirement of BSF-2/I1,6 for human multiple myelomas. Na-
ture (Lond.). 332:83 .
28 . Epstein, M.A . 1984 . Burkitt's lymphoma : clues to the role
of malaria. Nature (Lond.). 312:398 .